KIMBERLY GORE: Open Payments
NPI 1700929296 · SAN ANTONIO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$654 in 34 payments from 9 companies in 2025. Trend: 2023 $310 · 2024 $112 · 2025 $654
Food & beverage: $654
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $321 |
| Janssen Biotech, Inc. | 6 | $95 |
| Madrigal Pharmaceuticals | 3 | $62 |
| Lilly USA, LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| GENZYME CORPORATION | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, SKYRIZI, DUPIXENT, OMVOH, CREON, VOWST.
Industry payments across FL — which companies pay providers there.
